Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Research & Development (2016 - 2026)

Oramed Pharmaceuticals filings provide 14 years of Research & Development readings, the most recent being $2.0 million for Q4 2025.

  • Quarterly Research & Development rose 36.07% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.4 million through Dec 2025, up 0.9% year-over-year, with the annual reading at $6.4 million for FY2025, 0.9% up from the prior year.
  • Research & Development hit $2.0 million in Q4 2025 for Oramed Pharmaceuticals, up from $1.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $21.0 million in Q3 2021 and bottomed at $957000.0 in Q3 2023.
  • Average Research & Development over 5 years is $4.2 million, with a median of $2.0 million recorded in 2025.
  • The largest annual shift saw Research & Development crashed 82.1% in 2023 before it surged 134.27% in 2024.
  • Oramed Pharmaceuticals' Research & Development stood at $21.0 million in 2021, then plummeted by 56.94% to $9.0 million in 2022, then crashed by 80.46% to $1.8 million in 2023, then fell by 17.27% to $1.5 million in 2024, then soared by 36.07% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Research & Development are $2.0 million (Q4 2025), $1.2 million (Q3 2025), and $1.0 million (Q2 2025).